|
Health
|
Harry's Psychedelic Journey: A Glimmer of Hope Amidst Setbacks
2024-08-10 23:55:08
Health
Science

Harry's Psychedelic Journey: A Glimmer of Hope Amidst Setbacks

After a brain aneurysm, Harry turned to psilocybin therapy, finding solace in its potential to alleviate treatment-resistant depression and PTSD. Despite FDA declining approval for MDMA therapy, the demand for psychedelics is soaring.

With up to 60 hours of therapy needed, researchers strive to unveil the therapeutic benefits of psychedelics, long stigmatized due to the war on drugs. The National Drug Strategy Household Survey revealed a surge in hallucinogen use in Australia, underscoring a shift towards exploring unconventional treatments for mental health issues.

The press radar on this topic:

New York Times - Business
10. August 2024 um 11:56

F.D.A. Declines to Approve MDMA Therapy, Seeking More Study

Politics
The FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder, despite hopes from those with intractable mental health conditions. Lykos Therapeutics sought approval, but the agency said more data is needed, after independent experts convened in June rejected the company's application, finding insufficient evidence of effectiveness and safety. This was a setback for researchers like Michael Pollan and the UC Berkeley Center for the Science of Psychedelics, who aim to dem..
SBS News
10. August 2024 um 20:39

Harry's future looked bleak. Then he tried psychedelics

After a brain aneurysm, Harry researched psilocybin and MDMA - psychedelics approved in Australia for treating conditions like the 30% of people with treatment-resistant depression, as well as PTSD. With his father's support, he accessed psilocybin therapy, which he credits with boosting his recovery. Psychiatrist Dr. David Graham notes increasing demand, but a full course requires multiple sessions and up to 60 hours of therapy. The National Drug Strategy Household Survey found about 500,000..
CW

Account

Waiting list for the personalized area


Welcome!

InfoBud.ai

infobud.ai is an AI-driven news aggregator that simplifies global news, offering customizable feeds in all languages for tailored insights into tech, finance, politics, and more. It provides precise, relevant news updates, overcoming conventional search tool limitations. Due to the diversity of news sources, it provides precise and relevant news updates, focusing entirely on the facts without influencing opinion. Read moreExpand

Spotlighting today's most mentioned stocks in the media. Uncover the stories making waves in the stock market:

A closer look at the individuals who are leading today's news narratives. Find out what makes them the center of attention.

Exploring the five locations receiving the most media attention in the last 24 hours. Discover what puts these places in the global spotlight

Your World, Tailored News: Navigate The News Jungle With AI-Powered Precision!

News

All News
Politics
Technology
Economy
Business
Climate

About

About Us
Team + Mission

Legal

Cookie Settings
Disclaimer
Legal Notice
Data Privacy

Contact

Contact